/DISREGARD RELEASE: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./

We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer, issued 11-Jun-2025 over PR Newswire.

SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.